首页> Thoracic cancer> ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy.

ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jia,Zhong

第一单位： Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology-I, Peking University Cancer Hospital & Institute, Beijing, China.

作者： Jia,Zhong ^[1] ; Zihan,Guo ^[2] ; Liping,Fan ^[2] ; Xinghui,Zhao ^[1] ; Bingqing,Zhao ^[2] ; Zhigang,Cao ^[3] ; Linlin,Cheng ^[4] ; Yuanyuan,Shi ^[3] ; Xiaoting,Li ^[5] ; Yanhua,Zhang ^[2] ; Tongtong,An ^[1] ; Meina,Wu ^[1] ; Yuyan,Wang ^[1] ; Minglei,Zhuo ^[1] ; Jianjie,Li ^[1] ; Xue,Yang ^[1] ; Hanxiao,Chen ^[1] ; Bo,Jia ^[1] ; Jun,Zhao ^[1]

作者单位： Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology-I, Peking University Cancer Hospital & Institute, Beijing, China. ^[1] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pharmacy, Peking University Cancer Hospital & Institute, Beijing, China. ^[2] Department of Medical Oncology, Mancheng People's Hospital, Baoding, China. ^[3] Deportment of Medical Oncology, Dong'e People's Hospital, Liaocheng, China. ^[4] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiology, Peking University Cancer Hospital & Institute, Beijing, China. ^[5]

关键词 ABCB1 chemotherapy lung cancer pharmacokinetic